LEVATOL
LOE Approachingpenbutolol sulfate
NDAORALTABLET
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEVATOL (penbutolol sulfate) is an oral beta-blocker approved in 1987 for cardiovascular indications, likely hypertension and/or angina based on its pharmacological class. It is a small-molecule antihypertensive agent administered as a tablet.
LOE Approaching
As a decades-old product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on defensive strategies and generic transition planning with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEVATOL presents minimal career opportunity; the product is in end-of-life management mode with zero linked open positions and no growth trajectory. Professionals assigned here should expect focus on cost-containment, reimbursement defense, and transition planning rather than market expansion.
Managed Care Account ManagerGeneric Defense Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.